NEW YORK, NY — Protheragen, a professional service provider specializing in advanced drug delivery system development, has rolled out integrated solutions covering hydrogel drug delivery systems, microneedle development, and lyophilized flash release formulations. These offerings address key challenges in traditional drug administration, such as unstable efficacy, low bioavailability, frequent dosing, and limited targeting capabilities, providing diversified and customizable options for the global pharmaceutical and biomedical industries.
The hydrogel drug delivery system from Protheragen leverages the excellent biocompatibility and three-dimensional cross-linked polymer network structure of hydrogels to encapsulate various therapeutic substances, including small molecules, proteins, peptides, and nucleic acids. These hydrogel platforms can be engineered to respond to stimuli such as pH, temperature, and enzymes, enabling targeted and sustained drug release at designated body sites. This approach minimizes off-target side effects and improves the therapeutic index. Protheragen develops multiple practical hydrogel formulations tailored to diverse administration routes, including injectable, implantable, ocular, transdermal, oral, and nanoparticle-combined hydrogels. For instance, injectable hydrogels transform from liquid to solid gel under physiological conditions for long-term sustained release, while ocular hydrogels can be integrated into contact lenses to achieve non-invasive eye medication delivery. The company adopts both physical and chemical crosslinking methods to regulate hydrogel degradation, swelling, and deformation, achieving precise control over drug release rates.
Additionally, Protheragen's professional microneedle development services focus on transdermal drug delivery, a breakthrough novel drug delivery system that uses micron-sized needles to penetrate the skin's stratum corneum and deliver drugs directly to subcutaneous tissues. This technology bypasses gastrointestinal metabolism, significantly enhancing drug bioavailability and enabling localized treatment to reduce systemic adverse reactions. Protheragen develops five mainstream microneedle types: coated, dissolving, hollow, hydrogel-forming, and solid microneedles, supporting multiple delivery approaches such as "coat and poke" and "poke and release." From material selection, structural design, and formulation optimization to preclinical evaluation and production scale-up, the one-stop microneedle development workflow meets the personalized demands of different drugs and treatment scenarios.
Complementing these technologies, the lyophilized flash release formulation development service combines freeze-drying and flash-release technologies to optimize drug stability and release performance. Lyophilization converts liquid drugs into solid forms such as particles, films, and microspheres, effectively extending shelf life and protecting active pharmaceutical ingredients from degradation. Equipped with controlled release technologies, these formulations realize rapid or timed drug release after administration, covering oral, injectable, and topical application scenarios. Protheragen optimizes the entire production process from initial demand consultation and formulation design to freeze-drying parameter adjustment and quality testing, ensuring each batch of products complies with strict regulatory standards and facilitating subsequent commercial production and market approval for clients.
Collectively, these drug delivery system solutions deliver comprehensive services for global pharmaceutical and biomedical clients. With flexible customization capabilities, Protheragen's services adapt to drugs of different properties and clinical needs, helping research institutions and pharmaceutical enterprises accelerate the research and transformation of new drugs.
